Eli Lilly reports positive Phase 3 SHINE-2 trial results for Omvoh in pediatric ulcerative colitis
FROM THE WIRE · GURUFOCUS.COM
On October 19, 2026, Eli Lilly and Co (NYSE: LLY) announced encouraging results from its Phase 3 SHINE-2 trial evaluating Omvoh for pediatric patients with mode
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA positive Phase 3 readout can support expectations for Lilly's drug pipeline, though the share price impact is likely limited.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Lilly announced encouraging results from its Phase 3 SHINE-2 trial.
- 02The trial evaluates Omvoh in pediatric patients with ulcerative colitis.
- 03The announcement was made on October 19, 2026.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets